
Results from AceLink’s Phase 2 AL01211 Study in Fabry Disease Presented at WORLD Symposium 2025
Results from AceLink’s Phase 2 AL01211 Study in Fabry Disease Presented at WORLD Symposium 2025 AceLink Therapeutics, a clinical-stage biotech firm focused on developing next-generation oral substrate reduction therapies (SRTs),…












